ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.
- Mechanism
- Curator reviewed
ANA975 is an oral prodrug of isatoribine, a small molecule toll-like receptor 7 (TLR-7) agonist. Isatoribine is a patented nucleoside analog Anadys is developing for the treatment of HCV infection. Isatoribine is one of a new class of drugs being developed by Anadys to regulate innate immunity, combat HCV infection and overcome limitations of current therapies. Anadys believes isatoribine interacts with a specific receptor, Toll-like receptor 7, or TLR7, that is present on certain immune system cells.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C), infectious and parasitic disease (unspecified), and viral infection.Curator reviewed
- Formula / weight
- C14H16N4O7S · 384.36 g/mol (avg)
- Also known as
- ((2R,3R,4R,5R)-4-ACETOXY-5-(5-AMINO-2-OXO-THIAZOLO(4,5-D)PYRIMIDIN-3-YL)-2-(HYDROXYMETHYL)TETRAHYDROFURAN-3-YL) ACETATE · AN 975 · ISOTORABINE · THIAZOLO(4,5-D)PYRIMIDIN-2(3H)-ONE, 5-AMINO-3-(2,3-DI-O-ACETYL-.BETA.-D-RIBOFURANOSYL)-
- Code names
- ANA975
Resolves to
ZWELIJXAKMASLK-UGKPPGOTSA-NSMILES[H][C@]1(CO)O[C@@]([H])(N2C(=O)SC3=CNC(=N)N=C23)[C@]([H])(OC(C)=O)[C@]1([H])OC(C)=OWhat you can answer from here — as of April 02, 2025
Which drugs share a target with ANA975, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account